Application of electroporation in DNA vaccination protocols. (Articolo in rivista)

Type
Label
  • Application of electroporation in DNA vaccination protocols. (Articolo in rivista) (literal)
Anno
  • 2010-01-01T00:00:00+01:00 (literal)
Alternative label
  • Chiarella P.1,2; Fazio V.M.1; Signori E.1,2 (2010)
    Application of electroporation in DNA vaccination protocols.
    in Current gene therapy (Print)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Chiarella P.1,2; Fazio V.M.1; Signori E.1,2 (literal)
Pagina inizio
  • 281 (literal)
Pagina fine
  • 286 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 10 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 4 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1 Laboratory of Molecular Medicine and Biotechnology, CIR, University Campus Bio-Medico of Rome, Via A del Portillo 21, 00128 Rome, Italy; 2 Institute of Neurobiology and Molecular Medicine-ARTOV, CNR via Fosso del Cavaliere 100, 00133-Rome, Italy. (literal)
Titolo
  • Application of electroporation in DNA vaccination protocols. (literal)
Abstract
  • Vaccination is historically one of the most important methods for preventing infectious diseases in humans and animals. Due to recent advances in understanding the biology of the immune system, a more rational design of vaccines and vaccination strategies such as those based on gene transfer has been proposed. In particular, naked DNA vaccination is emerging as a promising approach for introducing foreign antigens into the host, inducing protective immunity against infectious diseases and malignant tumours. Plasmid DNA vaccines offer several advantages in comparison to traditional vaccines such as safety, tolerability and feasibility in manufacture. Nevertheless, because of their poor immunogenicity, plasmid DNA vaccines need further implementation. Recent data suggest electroporation as a useful strategy to improve DNA-based vaccination protocols, being able to stimulate both the humoural and cellular immune responses. In preclinical trials, electroporation is successfully used in prime-boost combination protocols and its efficacy and tolerability have been demonstrated in Phase I clinical trials. Since these initial results appear promising, in the next future we will assist further developments of naked DNA vaccination associated to the electroporation technology. This approach not only provides the basis for human studies but also a practical application to veterinary medicine. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Insieme di parole chiave di
data.CNR.it